PCI Pharma Expands Serialization CapacityBy
Part of the special news roundup of DCAT member companies for the DCAT Week ’17 Special Edition of DCAT Value Chain Insights (April 5, 2017)
PCI Pharma Services (PCI), a Philadelphia, Pennsylvania-headquartered pharmaceutical services provider, expanded its serialization capability and will triple its serialization capacity across its global supply network in advance of upcoming requirements due in 2017 under the US Drug Supply Chain Security Act and in 2019 under the European Union False Medicines Directive.
PCI partnered with Antares Vision, a Moorestown, New Jersey-headquartered provider of serialization-based track and trace solutions for the pharmaceutical industry, Marchesini, a Bologna, Italy-headquartered pharmaceutical packaging company, and Domino, a Cambridge, UK-headquartered producer of printing, coding and marking solutions for the pharmaceutical and healthcare industries, for this latest installation.
PCI is using Antares’ serialization platform and technology architecture across a variety of serialization technology platforms and applications. The multi-site installations support a variety of drug delivery forms, including bottles, unit cartons, and parenteral kits as well as unit dose wallets and child resistant/compliance prompting packaging. In addition, serialization technologies support ancillary and tertiary packaging, corrugated shippers, and palletization solutions for supporting multi-level product aggregation.
PCI’s recent serialization expansion follows its announcement in late 2016 that it is investing in site capacity expansion for it commercial contract packaging services. PCI sites in Philadelphia and in Rockford, Illinois also added multiple primary packaging lines including blister packaging, bottling, and pouch/sachet filling technologies.
PCI has been actively serializing commercial products for both domestic and international markets for the past five years, with products destined for North America and Europe, in addition to emerging markets such as South Korea, Turkey, Brazil, China, and others.
Source: PCI Pharma Services